HWKN · Hawkins Inc - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Revenue | $1.08B | $974.43M | $919.16M | $935.10M | $774.54M | $596.87M |
| Cost of Revenue | $838.64M | $748.89M | $725.53M | $769.98M | $628.02M | $473.11M |
| Gross Profit | $245.06M | $225.54M | $193.64M | $165.12M | $146.52M | $123.76M |
| R&D | - | - | - | - | - | - |
| SG&A | $123.76M | $106.36M | $89.60M | $76.97M | $75.33M | $67.88M |
| Total Operating Expenses | - | - | - | - | - | - |
| D&A | $52.54M | $39.95M | $31.80M | $27.44M | $24.13M | $22.67M |
| Operating Income | $121.29M | $119.17M | $104.04M | $88.15M | $71.19M | $55.88M |
| Interest Expense | - | - | - | - | - | - |
| Income Tax | $27.79M | $30.04M | $25.78M | $22.54M | $18.44M | $14.87M |
| Net Income | $81.55M | $84.34M | $75.36M | $60.04M | $51.54M | $40.98M |
| EPS - Basic | $3.93 | $4.05 | $3.61 | $2.88 | $2.46 | $1.95 |
| EPS - Diluted | $3.91 | $4.03 | $3.59 | $2.86 | $2.44 | $1.93 |
Balance Sheet
| Line item | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $3.91M | $5.10M | $7.15M | $7.57M | $3.50M | $3.00M |
| Accounts Receivable | $139.80M | $131.79M | $114.48M | $129.25M | $122.83M | $90.60M |
| Inventory | $78.20M | $83.51M | $74.60M | $88.78M | $94.98M | $63.86M |
| Accounts Payable | $59.84M | $61.20M | $56.39M | $53.70M | $66.69M | $37.31M |
| Current Assets | $231.47M | $230.69M | $202.83M | $232.04M | $227.74M | $163.01M |
| Total Assets | $986.29M | $769.87M | $657.93M | $590.53M | $567.33M | $472.55M |
| Current Liabilities | $104.84M | $107.14M | $103.31M | $90.87M | $101.47M | $70.46M |
| Long-term Debt | $244.00M | $138.91M | $88.82M | $101.73M | $115.64M | $88.84M |
| Total Liabilities | $452.28M | $309.57M | $251.91M | $240.52M | $264.73M | $207.30M |
| Stockholders' Equity | $534.01M | $460.29M | $406.03M | $350.02M | $302.60M | $265.25M |
| Retained Earnings | $500.14M | $434.26M | $364.55M | $302.42M | $254.38M | $213.90M |
Cash Flow
| Line item | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | $144.33M | $111.10M | $159.50M | $77.40M | $42.84M | $43.79M |
| Investing Cash Flow | ($224.10M) | ($127.95M) | ($122.50M) | ($41.23M) | ($49.76M) | ($71.43M) |
| Financing Cash Flow | $78.58M | $14.81M | ($37.41M) | ($32.10M) | $7.42M | $26.36M |
| CapEx | $58.24M | $41.10M | $40.15M | $48.32M | $28.51M | $20.79M |
| Free Cash Flow | $86.09M | $70.00M | $119.35M | $29.08M | $14.32M | $23.00M |
Ratios
| Metric | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 22.6% | 23.1% | 21.1% | 17.7% | 18.9% | 20.7% |
| Operating margin | 11.2% | 12.2% | 11.3% | 9.4% | 9.2% | 9.4% |
| EBITDA margin | 16.0% | 16.3% | 14.8% | 12.4% | 12.3% | 13.2% |
| Net margin | 7.5% | 8.7% | 8.2% | 6.4% | 6.7% | 6.9% |
| Free cash flow margin | 7.9% | 7.2% | 13.0% | 3.1% | 1.8% | 3.9% |
| FCF / Net income | 1.06 | 0.83 | 1.58 | 0.48 | 0.28 | 0.56 |
| R&D / Revenue | - | - | - | - | - | - |
| SG&A / Revenue | 11.4% | 10.9% | 9.7% | 8.2% | 9.7% | 11.4% |
| Effective tax rate | 25.4% | 26.3% | 25.5% | 27.3% | 26.3% | 26.6% |
| Return on assets | 8.3% | 11.0% | 11.5% | 10.2% | 9.1% | 8.7% |
| Return on equity | 15.3% | 18.3% | 18.6% | 17.2% | 17.0% | 15.4% |
| Return on invested capital | 11.6% | 14.7% | 15.7% | 14.2% | 12.5% | 11.6% |
| Liquidity | ||||||
| Current ratio | 2.21 | 2.15 | 1.96 | 2.55 | 2.24 | 2.31 |
| Quick ratio | 1.46 | 1.37 | 1.24 | 1.58 | 1.31 | 1.41 |
| Cash ratio | 0.04 | 0.05 | 0.07 | 0.08 | 0.03 | 0.04 |
| Leverage | ||||||
| Debt / Equity | 0.46 | 0.30 | 0.22 | 0.29 | 0.38 | 0.33 |
| Debt / Assets | 0.25 | 0.18 | 0.13 | 0.17 | 0.20 | 0.19 |
| Debt / EBITDA | 1.40 | 0.87 | 0.65 | 0.88 | 1.21 | 1.13 |
| Interest coverage | - | - | - | - | - | - |
| Equity multiplier | 1.85 | 1.67 | 1.62 | 1.69 | 1.87 | 1.78 |
| Liabilities / Assets | 0.46 | 0.40 | 0.38 | 0.41 | 0.47 | 0.44 |
| Efficiency | ||||||
| Asset turnover | 1.10 | 1.27 | 1.40 | 1.58 | 1.37 | 1.26 |
| Inventory turnover | 10.72 | 8.97 | 9.73 | 8.67 | 6.61 | 7.41 |
| Days sales outstanding | 47d | 49d | 45d | 50d | 58d | 55d |
| Days inventory outstanding | 34d | 41d | 38d | 42d | 55d | 49d |
| Days payable outstanding | 26d | 30d | 28d | 25d | 39d | 29d |
| Cash conversion cycle | 55d | 60d | 55d | 67d | 74d | 76d |
| Valuation | ||||||
| P / E | 38.9x | 26.3x | 21.4x | 15.3x | 18.7x | 17.3x |
| P / B | 5.9x | 4.8x | 4.0x | 2.6x | 3.2x | 2.7x |
| P / S | 2.9x | 2.3x | 1.8x | 1.0x | 1.2x | 1.2x |
| EV / EBITDA | 19.6x | 14.8x | 12.5x | 8.8x | 11.3x | 10.2x |
| Growth | ||||||
| Revenue growth (YoY) | 11.2% | 6.0% | -1.7% | 20.7% | 29.8% | - |
| Revenue CAGR (3y) | 5.0% | 8.0% | 15.5% | - | 12.8% | 2.4% |
| Revenue CAGR (5y) | 12.7% | - | 11.2% | 10.9% | 13.3% | 10.4% |
| Gross profit growth (YoY) | 8.7% | 16.5% | 17.3% | 12.7% | 18.4% | - |
| Operating income growth (YoY) | 1.8% | 14.6% | 18.0% | 23.8% | 27.4% | - |
| Net income growth (YoY) | -3.3% | 11.9% | 25.5% | 16.5% | 25.8% | - |
| EPS growth (YoY) | -3.0% | 12.3% | 25.5% | 17.2% | 26.4% | - |
| EPS CAGR (3y) | 11.0% | 18.2% | 23.0% | - | -2.8% | -5.4% |
| EPS CAGR (5y) | 15.2% | - | 6.2% | 4.6% | - | -2.0% |
| FCF growth (YoY) | 23.0% | -41.3% | 310.4% | 103.0% | -37.7% | - |
| FCF CAGR (5y) | 30.2% | - | 28.3% | -3.8% | 13.4% | -0.2% |
| Book value growth (YoY) | 16.0% | 13.4% | 16.0% | 15.7% | 14.1% | - |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2026-03-29.
Business segments
$1.08B totalWater Treatment$543.30M · 50.1%
Food And Health Sciences$320.70M · 29.6%
Industrial Solutions$219.69M · 20.3%
Product / service
$861.00M totalManufacturedblendedorrepackagedproducts$488.62M · 56.8%
Nutrition$137.99M · 16.0%
Food$99.28M · 11.5%
Agricultural$52.56M · 6.1%
Bulk$49.58M · 5.8%
Pharmaceutical$27.87M · 3.2%
Other$5.11M · 0.6%
Stability scores
Altman Z′
FY 2026 · bankruptcy risk
2.50
Grey zone
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2026 · 9-point quality
5/9
Neutral
- ✓Net income positive
- ✓Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- ✗Long-term debt decreased
- ✓Current ratio improved
- ✓No share dilution
- ✗Gross margin improved
- ✗Asset turnover improved
Peer comparison
Same SIC group: Wholesale-Chemicals & Allied Products
Comparing HAWKINS INC against the 2 most active filers in the same SIC group.
Dividends
$0.76/share trailing 12 months · +5.6% YoY
| Ex-date | Per share |
|---|---|
| May 29, 2026 | $0.1900 |
| Feb 13, 2026 | $0.1900 |
| Nov 14, 2025 | $0.1900 |
| Aug 15, 2025 | $0.1900 |
| May 30, 2025 | $0.1800 |
| Feb 14, 2025 | $0.1800 |
| Nov 15, 2024 | $0.1800 |
| Aug 16, 2024 | $0.1800 |
| May 31, 2024 | $0.1600 |
| Feb 15, 2024 | $0.1600 |
| Nov 16, 2023 | $0.1600 |
| Aug 17, 2023 | $0.1600 |
| Jun 1, 2023 | $0.1500 |
| Feb 16, 2023 | $0.1500 |
| Nov 17, 2022 | $0.1400 |
| Aug 18, 2022 | $0.1400 |
| Jun 2, 2022 | $0.1400 |
| Feb 17, 2022 | $0.1400 |
| Nov 4, 2021 | $0.1300 |
| Aug 12, 2021 | $0.1300 |
| Jun 3, 2021 | $0.1230 |
| Feb 11, 2021 | $0.1225 |
| Nov 5, 2020 | $0.1165 |
| Aug 13, 2020 | $0.1165 |